Pelkey T J, Frierson H F, Mills S E, Stoler M H
Department of Pathology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Hum Pathol. 1999 Jan;30(1):26-31. doi: 10.1016/s0046-8177(99)90296-4.
Placental trophoblasts are the primary source of serum inhibin during pregnancy. We sought to characterize inhibin immunolabeling in trophoblastic neoplasms and compare the results with those for established markers of trophoblastic differentiation. Formalin-fixed, paraffin-embedded tissues from three normal term placentas, 13 hydatidiform moles (HM), five choriocarcinomas (CC) (three gestational, one testicular, one mediastinal), and five placental site trophoblastic tumors (PSTT) were immunolabeled with antibodies to the alpha-subunit of inhibin, hPL, and beta-hCG. Additionally, six first-trimester placentas were immunolabeled with antibody to inhibin alone. Trophoblastic subpopulations were assessed for the number of positive cells (1% to 24% = 1+,25% to 49% = 2+,50% to 74% = 3+, 75% to 100% = 4+). Immunolabeling in term placenta and HM was similar, because beta-hCG was the most sensitive marker (4+) of syncytiotrophoblasts followed by inhibin (3-4+) and hPL (2-3+). Immunolabeling of syncytiotrophoblasts in CC was similar to that in term placenta and HM, except for negative hPL staining in two cases. In HM, inhibin labeling of intermediate trophoblasts (2-3+) was less than that for hPL (3-4+). In CC, inhibin and hPL labeling of intermediate trophoblasts was more variable with negative hPL reactivity in two cases. Inhibin and hPL did not stain cytotrophoblasts. In PSTT, inhibin immunolabeling was a better marker than hPL in two cases, inferior in two, and similar in one. Inhibin labeling of syncytiotrophoblasts was less than that for beta-hCG, but did not have the often marked background staining that was present with beta-hCG. Immunolabeling of trophoblast subpopulations for inhibin was similar between first-trimester placenta, term placenta, and HM. We conclude that inhibin is a useful immunohistochemical marker of trophoblastic neoplasia and should be included in the antibody panel with beta-hCG and hPL.
胎盘滋养层细胞是孕期血清抑制素的主要来源。我们试图对滋养层肿瘤中的抑制素免疫标记进行特征描述，并将结果与滋养层分化的既定标志物的结果进行比较。对来自三个足月正常胎盘、13例葡萄胎（HM）、五例绒毛膜癌（CC）（三例妊娠性、一例睾丸性、一例纵隔性）和五例胎盘部位滋养层肿瘤（PSTT）的福尔马林固定、石蜡包埋组织用抗抑制素α亚基、人胎盘催乳素（hPL）和β-人绒毛膜促性腺激素（β-hCG）的抗体进行免疫标记。此外，对六个孕早期胎盘仅用抗抑制素抗体进行免疫标记。评估滋养层亚群的阳性细胞数量（1%至24% = 1+，25%至49% = 2+，50%至74% = 3+，75%至100% = 4+）。足月胎盘和葡萄胎中的免疫标记相似，因为β-hCG是合体滋养层细胞最敏感的标志物（4+），其次是抑制素（3 - 4+）和hPL（2 - 3+）。绒毛膜癌中合体滋养层细胞的免疫标记与足月胎盘和葡萄胎相似，只是有两例hPL染色为阴性。在葡萄胎中，中间型滋养层细胞的抑制素标记（2 - 3+）低于hPL（3 - 4+）。在绒毛膜癌中，中间型滋养层细胞的抑制素和hPL标记变化更大，有两例hPL反应性为阴性。抑制素和hPL未对细胞滋养层细胞染色。在胎盘部位滋养层肿瘤中，两例中抑制素免疫标记比hPL更好，两例较差，一例相似。合体滋养层细胞的抑制素标记低于β-hCG，但没有β-hCG常见的明显背景染色。孕早期胎盘、足月胎盘和葡萄胎之间滋养层亚群的抑制素免疫标记相似。我们得出结论，抑制素是滋养层肿瘤的一种有用的免疫组织化学标志物，应与β-hCG和hPL一起列入抗体组。
